Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Analysis report covers drugs of 8 companies currently in different phases of development. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disease which impairs the sensory functions in arms and legs. It is also sometimes known as chronic relapsing polyneuropathy. This causes damage to the myelin sheath (protects the nerve fibres) and affects the peripheral nerves. The disease can affect both the genders but is more common in males. However, the exact cause of the disorder is not known but is an autoimmune disorder. Symptoms include numbness of toes and fingers, fatigue, weakness of limbs and abnormal sensations.
The report provides Chronic Inflammatory Demyelinating Polyneuropathy treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Octapharma, Shire, CSL and Pfizer Inc. among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration